PharmaTimes reports that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Nuformix to commence its NXP001 human pharmacokinetics study. Nuformix is developing NXP001 as a treatment for chemotherapy-induced nausea and vomiting, a large,...